Alyeska Investment Group L.P. acquired a new stake in Aktis Oncology (NASDAQ:AKTS - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 290,000 shares of the technology company's stock, valued at approximately $9,347,000. Alyeska Investment Group L.P. owned about 0.54% of Aktis Oncology as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in the business. State of Wyoming acquired a new position in Aktis Oncology in the 2nd quarter valued at about $32,000. Deutsche Bank AG raised its holdings in Aktis Oncology by 49.3% in the 2nd quarter. Deutsche Bank AG now owns 21,022 shares of the technology company's stock valued at $678,000 after acquiring an additional 6,942 shares during the period. Great Lakes Advisors LLC acquired a new stake in Aktis Oncology during the second quarter worth approximately $1,406,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Aktis Oncology by 2.2% during the second quarter. The Manufacturers Life Insurance Company now owns 48,044 shares of the technology company's stock worth $1,548,000 after acquiring an additional 1,051 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in Aktis Oncology by 14.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 49,250 shares of the technology company's stock worth $1,587,000 after purchasing an additional 6,349 shares during the last quarter. 28.84% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In other Aktis Oncology news, Director Ken Herrmann sold 4,856 shares of the company's stock in a transaction on Monday, July 20th. The stock was sold at an average price of $24.56, for a total transaction of $119,263.36. Following the completion of the sale, the director directly owned 3,506 shares in the company, valued at $86,107.36. This represents a 58.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Aktis Oncology Stock Up 0.5%
AKTS opened at $25.91 on Tuesday. Aktis Oncology has a twelve month low of $14.72 and a twelve month high of $34.19. The company has a 50-day simple moving average of $25.83 and a 200 day simple moving average of $21.57. The stock has a market capitalization of $1.39 billion and a price-to-earnings ratio of -31.60.
Aktis Oncology (NASDAQ:AKTS - Get Free Report) last issued its earnings results on Thursday, August 13th. The technology company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The firm had revenue of $3.38 million for the quarter, compared to the consensus estimate of $2.70 million. Sell-side analysts anticipate that Aktis Oncology will post -1.8 EPS for the current fiscal year.
Analyst Ratings Changes
AKTS has been the subject of a number of recent research reports. Wedbush began coverage on shares of Aktis Oncology in a research report on Wednesday, August 19th. They issued an "outperform" rating and a $35.00 target price for the company. JPMorgan Chase & Co. raised their price target on shares of Aktis Oncology from $30.00 to $33.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 14th. Weiss Ratings raised shares of Aktis Oncology from a "sell (d)" rating to a "sell (d+)" rating in a report on Tuesday, June 23rd. Raymond James Financial began coverage on shares of Aktis Oncology in a research report on Monday, June 15th. They set a "strong-buy" rating and a $40.00 target price on the stock. Finally, BMO Capital Markets started coverage on shares of Aktis Oncology in a report on Tuesday, August 18th. They set an "outperform" rating and a $37.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $35.00.
View Our Latest Report on Aktis Oncology
About Aktis Oncology
(
Free Report)
Aktis Oncology NASDAQ: AKTS is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.
The company's activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.
Further Reading
Want to see what other hedge funds are holding AKTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aktis Oncology (NASDAQ:AKTS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Aktis Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aktis Oncology wasn't on the list.
While Aktis Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
